PRECLINICAL SAFETY AND IMMUNOGENICITY OF CONTREVIR IN CHIMPANZEES

CONTREVIR 在黑猩猩中的临床前安全性和免疫原性

• 批准号: 8357711
• 负责人: Krishna K Murthy
• 金额: $ 20.83万
• 依托单位: TEXAS BIOMEDICAL RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357711
• 关键词: AIDS/HIV problem; Biopsy Specimen; Blood; Blood Cell Count; Clinical Chemistry; Defective Viruses; Funding; Genes; Grant; HIV; HIV-1; Immune response; Immunotherapy; Infection; Monitor; National Center for Research Resources; Pan Genus; Primates; Principal Investigator; Research; Research Infrastructure; Resources; Safety; Source; Time; United States National Institutes of Health; Virus; Virus Replication; cost; immunogenicity; lymph nodes; preclinical safety

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The primary objective of this study is to develop a safe and effective immunotherapy for HIV-1 infection.Therefore, two na¿ve chimpanzees will be inoculated with a gene deleted HIV-1 isolate designated as Contrevir which is non-disease causing but replication competent. Two HIV na¿ve chimpanzees will be intravenously inoculated with the defective virus , blood and lymph node biopsy samples will be collected at various time points to determine replication of the virus and immunological response of the host to the virus. In addition blood cell counts and clinical chemistry parameters will be monitored to determine safety aspects. It is anticipated that administration of Contrevir will be safe and will induce robust immune responses in chimpanzees. If Contrevir is safe and effective, it will add an immunotherapy approach to the treatment of HIV/AIDS

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 本研究的主要目的是开发一种安全有效的HIV-1免疫疗法。因此，将用一种基因缺失的HIV-1分离株（命名为Contrevir）接种两只未感染过的黑猩猩，该分离株不致病，但具有复制能力。两个艾滋病毒感染者五只黑猩猩将接受有缺陷病毒的静脉注射，并在不同时间点收集血液及淋巴结活组织样本，以确定病毒的复制及宿主对病毒的免疫反应。此外，还将监测血细胞计数和临床生化参数，以确定安全性。预计给予Contrevir是安全的，并将在黑猩猩中诱导强烈的免疫应答。如果Contrevir是安全有效的，它将为艾滋病毒/艾滋病的治疗增加一种免疫治疗方法